Peggy Lipp und Debiopharm International Person-Info 

( Ich bin Peggy Lipp)
(1 - 12 von 13
)

EMA Grants Orphan Drug Designation to Debiopharm International SA's...

www.informazione.it
Orphan Drug Designation by the EMA provides regulatory and financial incentives to develop therapies for life-threatening or chronically debilitating…

FDA Grants Orphan Drug Designation to Debiopharm International SA's...

www.wallstreet-online.de
is an important regulatory milestone", stated Peggy Lipp, Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm

News for Medical Independent Sales Representatives and Medical...

salesandmarketingnetwork.com
Healthcare Sales & Marketing Network: FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio in the Treatment of Ovarian...

FDA grants fast track designation to Debio for FGFR

www.healio.com
— Peggy Lipp, director of regulatory affairs, market intelligence and market access at Debiopharm International, said in a company-issued ... › online
+1